Evidence map›Paper›PMID 37886750›Full record

ArticleHeliyon2023

Design, synthesis and anticancer evaluation of polymethoxy aurones as potential cell cycle inhibitors.

Zheng Wu, Yaoyao Han, Xiaolan Li, Qiuping Zhang, Renjin Deng, Hong Ren, Wenjing He, Xinduo Wu, Hongwei Guo, Dan Zhu

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zheng WuGuangxi Key Laboratory of Bioactive Molecules Research and Evaluation & Guangxi Health Commission Key Laboratory of Basic Research on Antigeriatric Drugs, College of Pharmacy, Guangxi Medical University, Nanning, 530021, China.
Yaoyao HanGuangxi Key Laboratory of Bioactive Molecules Research and Evaluation & Guangxi Health Commission Key Laboratory of Basic Research on Antigeriatric Drugs, College of Pharmacy, Guangxi Medical University, Nanning, 530021, China.
Xiaolan LiGuangxi Key Laboratory of Bioactive Molecules Research and Evaluation & Guangxi Health Commission Key Laboratory of Basic Research on Antigeriatric Drugs, College of Pharmacy, Guangxi Medical University, Nanning, 530021, China.
Qiuping ZhangKey Laboratory of Longevity and Aging-related Diseases of Chinese Ministry of Education & Center for Translational Medicine, Guangxi Medical University, Nanning, 530021, China.
Renjin DengGuangxi Key Laboratory of Bioactive Molecules Research and Evaluation & Guangxi Health Commission Key Laboratory of Basic Research on Antigeriatric Drugs, College of Pharmacy, Guangxi Medical University, Nanning, 530021, China.
Hong RenGuangxi Key Laboratory of Bioactive Molecules Research and Evaluation & Guangxi Health Commission Key Laboratory of Basic Research on Antigeriatric Drugs, College of Pharmacy, Guangxi Medical University, Nanning, 530021, China.
Wenjing HeGuangxi Key Laboratory of Bioactive Molecules Research and Evaluation & Guangxi Health Commission Key Laboratory of Basic Research on Antigeriatric Drugs, College of Pharmacy, Guangxi Medical University, Nanning, 530021, China.
Xinduo WuGuangxi Key Laboratory of Bioactive Molecules Research and Evaluation & Guangxi Health Commission Key Laboratory of Basic Research on Antigeriatric Drugs, College of Pharmacy, Guangxi Medical University, Nanning, 530021, China.
Hongwei GuoGuangxi Key Laboratory of Bioactive Molecules Research and Evaluation & Guangxi Health Commission Key Laboratory of Basic Research on Antigeriatric Drugs, College of Pharmacy, Guangxi Medical University, Nanning, 530021, China.
Dan ZhuGuangxi Key Laboratory of Bioactive Molecules Research and Evaluation & Guangxi Health Commission Key Laboratory of Basic Research on Antigeriatric Drugs, College of Pharmacy, Guangxi Medical University, Nanning, 530021, China.
Guangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cancer is the most fatal disease in humans and the aberrant activity of various cell cycle proteins results in uncontrolled tumor cell proliferation, thus, regulating the cell cycle is an attractive target in cancer therapy. Objectives: Aurone is a naturally occurring active compound with a wide range of biological activities, of which 3, 4, 5-trimethoxyphenyl (TMP) is an important microtubule targeting pharmacophore. Based on the pharmacophore combination principle, we incorporate the TMP pharmacophore into the aurone structure and design a novel polymethoxy derivative that is expected to inhibit tumor cell proliferation through regulating the cell cycle. Methods: By introducing different substituents on C-4' and C-3', a series of new 4, 5, 6-trimethoxy aurone derivatives have been designed and synthesized. DU145, MCF-7 and H1299 cell lines were selected to evaluate their anticancer activity. The compound with the best cytotoxicity was then selected and the anticancer mechanisms were investigated by network pharmacology, flow cytometry, Western blot, and cell heat transfer assay. ADMET prediction evaluated the draggability of aurone derivatives. Results: Aurones Conclusions: Polymethoxy aurones

Indexed as

ADMET predictionCell cycleCyclinB1/CDK1 inhibitorMolecular dockingNetwork pharmacologyPolymethoxy auronesProstate cancer

Identifiers

PMID37886750
PMCPMC10597867
OpenAlexW4387643724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.